Daiichi Pharmaceutical and Celestar Lexico-Sciences Completes Joint Research on Genome Drug.
Using CLS' proprietary in silico prediction technology, the collaboration has identified more than 220 protein-protein interactions, of which 44 disease-related interactions are currently patent pending.
Moreover, one of the results, "Activation of Telomerase by mitogen-activated protein kinase-activated protein kinase 3" was presented at the 64th Annual Meeting of the Japanese Cancer Association. The result is expected to serve a drug discovery target for the treatment of cancer.
Going forward, Daiichi Pharmaceutical will proceed with research on the newly-discovered protein-protein interactions with a view to leveraging them in the development of products.
Meanwhile, CLS plans to combine the in silico prediction technology with its proprietary large-scale in situ Hybridization (LisH) technique for applications in the drug target discovery and the safety evaluation of compounds while improving its technological capabilities.
Copyright [c] 2005 Japan Corporate News Network. All rights reserved.
|Printer friendly Cite/link Email Feedback|
|Publication:||JCNN News Summaries|
|Date:||Dec 6, 2005|
|Previous Article:||Kobayashi Pharmaceutical Confirms That Peppermint-Containing Food Helps Alleviate Atopic Dermatitis.|
|Next Article:||Toray, DNA Chip Research to Co-develop High-performance DNA Chip.|